Yinqi Li

Yinqi Li

Auto-generated profile, based on publicly available information

Yinqi Li

Department of Pharmacy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2024 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
YLYinqi Li
Yinqi Li
YZYeteng Zheng
Yeteng Zheng
TLTaiqing Liu
Taiqing Liu
CLChuanyun Liao
Chuanyun Liao
GSGuobo Shen
Guobo Shen
Zhiyao HeZhiyao He
Zhiyao He
Adoptive cell therapy has revolutionized cancer treatment, especially for hematologic malignancies. T cells are the most extensively utilized cells in adoptive cell therapy. Currently, tumor-infiltrating lymphocytes, T cell receptor-transgenic T cells and chimeric antigen receptor T cells are the three main adoptive T cell therapies. Tumor-infiltrating lymphocytes kill tumors by reinfusing enlarged lymphocytes that naturally target tumor-specific antigens into the patient. T cell receptor-transgenic T cells have the ability to specifically destroy tumor cells via the precise recognition of exogenous T cell receptors with major histocompatibility complex. Chimeric antigen receptor T cells transfer genes with specific antigen recognition structural domains and T cell activation signals into T cells, allowing T cells to attack tumors without the assistance of major histocompatibility complex. Many barriers have been demonstrated to affect the clinical efficacy of adoptive T cell therapy, such as tumor heterogeneity and antigen loss, hard trafficking and infiltration, immunosuppressive tumor microenvironment and T cell exhaustion. Several strategies to improve the efficacy of adoptive T cell therapy have been explored, including multispecific chimeric antigen receptor T cell therapy, combination with immune checkpoint blockade, targeting the immunosuppressive tumor microenvironment, etc. In this review, we will summarize the current status and clinical application, followed by major bottlenecks in adoptive T cell therapy. In addition, we will discuss the promising strategies to improve adoptive T cell therapy. Adoptive T cell therapy will result in even more incredible advancements in solid tumors if the aforementioned problems can be handled. Graphical abstract

1 December 2024 in Chemical Engineering Journal
Verified
Journal Article
Closed access
JZJinhua Zhao
Jinhua Zhao
TLTaiqing Liu
Taiqing Liu
YLYinqi Li
Yinqi Li
XYXiaodong Yang
Xiaodong Yang
XWXiaoyu Wang
Xiaoyu Wang
Zhiyao HeZhiyao He
Zhiyao He

22 July 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
YLYinqi Li
Yinqi Li
YZYeteng Zheng
Yeteng Zheng
TLTaiqing Liu
Taiqing Liu
JZJinhua Zhao
Jinhua Zhao
LZLingyan Zhou
Lingyan Zhou
Zhiyao HeZhiyao He
Zhiyao He